Now, with the MATTERHORN data, we’ve seen that when we start with Imfinzi—or an IO—in a perioperative setting, which ...

In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains ...

Gain insight into how the MATTERHORN trial’s results across PD-L1 subgroups could expand access to immunotherapy and reshape ...

Learn how increasing system complexity and patient-facing technologies are creating new burdens for clinical trial sites—and ...

Because the data [are] contextualized, we know who the physicians are [that are] working with the patients we aspire to treat ...

ACT: The MATTERHORN trial showed a 22% reduction in the risk of death with the Imfinzi regimen. How significant is this ...

Addressing the imbalance in clinical trial workloads by empowering mid-level investigators and using AI to expand access to ...

Examining how artificial intelligence can help identify true key opinion leaders in emerging markets to improve site ...

Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries ...

In today’s ACT Brief, we explore how AstraZeneca is redefining gastric cancer care through the MATTERHORN trial, Phesi’s Gen Li shares how AI and patient data are advancing global trial equity, and ...

Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...